Lorigerlimab for endometrial neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 12 Dec 2024: Trial registered, NCT06730347
  2. 1 May 2025: Trial started, NCT06730347

The trials

NCT06730347: A Study of Lorigerlimab in Participants With Advanced Solid Tumors

State
Under way
Phase
Phase 2
People
80 planned
Started
1 May 2025
Primary completion
Jul 2027
Arms
Cohort A (PROC) high dose, Cohort A (PROC) low dose, Cohort B (CCGC), Cohort C (CCGC)
Results
None posted
  1. 12 Dec 2024: Trial registered
  2. 1 May 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.